Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Bassam F. Matti"'
Impact of IDH Mutations on DNA Methylation of Acute Myeloid Leukemia Related Genes: A Review Article
Publikováno v:
مجلة كلية الطب, Vol 66, Iss 1 (2024)
Background: Acute myeloid leukemia is one of the deadliest hematologic malignancies that is marked by genetic alterations, abnormal cellular functions, and proliferation. Mutations in isocitrate dehydrogenase genes, particularly isocitrate dehydrogen
Externí odkaz:
https://doaj.org/article/bab726babcf54c6c99570199c8b44011
Autor:
Mohammed S. Abbas, Alaadin S. Naji, Ahmed A. AL - Saffar, Mazin A. Shubbar, Bassam F. Matti, Adil Siwan, Ammar F. Majeed, Ali M. Jawad
Publikováno v:
مجلة كلية الطب, Vol 57, Iss 2 (2015)
Background: Hodgkin disease was the first cancer in which the curative potential of combination chemotherapy was demonstrated. The affected patients are often young and there is a great potential for adding years of productive life by giving curative
Externí odkaz:
https://doaj.org/article/878189288dbd4553a0327aaf9745c52c
Publikováno v:
Mediterranean Journal of Hematology and Infectious Diseases, Vol 1 (2014)
Background and Objective: Refractory/relapsed acute leukemia has always been a challenging problem for hematologist. Over the past decade emphasis has been made in the development of regimens containing fludarabine, combined with cytosine arabinoside
Externí odkaz:
https://doaj.org/article/d39ee5bf8bfb4a56805f205c7e46011c
Publikováno v:
Asian Journal of Pharmaceutical and Clinical Research. 11:192
Objective: The assessment of neopterin and interferon-gamma (IFN-γ) levels as a part of immune system response about serum iron status in β-thalassemia (TM) major patients.Methods: Spectrophotometry applied for the estimation of iron status includi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::075f80f91fbc42df8b0251f4d3b5ff3b
https://doi.org/10.22159/ajpcr.2018.v11i9.26661
https://doi.org/10.22159/ajpcr.2018.v11i9.26661
Publikováno v:
Cancer and Clinical Oncology. 2
The development of Imatinib Mesylate (IM), the first generation specific tyrosine kinase inhibitor (TKI) of BCR-ABL, has had a major impact in patients with Chronic Myeloid Leukemia (CML), establishing IM as the standard therapy for CML. Despite the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3c0875c20df878a19c4d701b49495fa0
https://doi.org/10.5539/cco.v2n2p55
https://doi.org/10.5539/cco.v2n2p55
Publikováno v:
Journal of Molecular Biology Research. 1
Real-time quantitative (RQ-PCR) assays were developed to monitor the kinetics of residual BCR-ABL transcripts over time and to follow up chronic myeloid leukemia patients (CML) treated with imatinb mesylate (IM) for assessment of response at differen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::63f850e092c9056f96e18ab81c934665
https://doi.org/10.5539/jmbr.v1n1p47
https://doi.org/10.5539/jmbr.v1n1p47